Study identification

PURI

https://redirect.ema.europa.eu/resource/35906

EU PAS number

EUPAS32139

Study ID

35906

Official title and acronym

Targeted Literature Review to Describe Safety Outcomes in Immune Thrombocytopenia Patients Treated With Thrombopoietin-Receptor Agonists

DARWIN EU® study

No

Study countries

United States

Study status

Finalised
Research institutions and networks

Institutions

Amgen
United States
First published:
21/02/2024
Institution

Contact details

Global Development Leader Amgen Inc.

Primary lead investigator
Study timelines

Date when funding contract was signed

Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Amgen
Study protocol
Initial protocol
English (362.2 KB - PDF)View document
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable